Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72

Marka Van Blitterswijk, Tania D Gendron, Matthew C. Baker, Mariely DeJesus-Hernandez, NiCole C A Finch, Patricia H. Brown, Lillian M. Daughrity, Melissa E Murray, Michael G. Heckman, Jie Jiang, Clotilde Lagier-Tourenne, Dieter Edbauer, Don W. Cleveland, Keith Anthony Josephs, Joseph E Parisi, David S Knopman, Ronald Carl Petersen, Leonard Petrucelli, Bradley F Boeve, Neill R Graff RadfordKevin B. Boylan, Dennis W Dickson, Rosa V Rademakers

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The loss of chromosome 9 open reading frame 72 (C9ORF72) expression, associated with C9ORF72 repeat expansions, has not been examined systematically. Three C9ORF72 transcript variants have been described thus far; the GGGGCC repeat is located between two non-coding exons (exon 1a and exon 1b) in the promoter region of transcript variant 2 (NM_018325.4) or in the first intron of variant 1 (NM_145005.6) and variant 3 (NM_001256054.2). We studied C9ORF72 expression in expansion carriers (n = 56) for whom cerebellum and/or frontal cortex was available. Using quantitative real-time PCR and digital molecular barcoding techniques, we assessed total C9ORF72 transcripts, variant 1, variant 2, variant 3, and intron containing transcripts [upstream of the expansion (intron 1a) and downstream of the expansion (intron 1b)]; the latter were correlated with levels of poly(GP) and poly(GA) proteins aberrantly translated from the expansion as measured by immunoassay (n = 50). We detected a decrease in expansion carriers as compared to controls for total C9ORF72 transcripts, variant 1, and variant 2: the strongest association was observed for variant 2 (quantitative real-time PCR cerebellum: median 43 %, p = 1.26e-06, and frontal cortex: median 58 %, p = 1.11e-05; digital molecular barcoding cerebellum: median 31 %, p = 5.23e-10, and frontal cortex: median 53 %, p = 5.07e-10). Importantly, we revealed that variant 1 levels greater than the 25th percentile conferred a survival advantage [digital molecular barcoding cerebellum: hazard ratio (HR) 0.31, p = 0.003, and frontal cortex: HR 0.23, p = 0.0001]. When focusing on intron containing transcripts, analysis of the frontal cortex revealed an increase of potentially truncated transcripts in expansion carriers as compared to controls [digital molecular barcoding frontal cortex (intron 1a): median 272 %, p = 0.003], with the highest levels in patients pathologically diagnosed with frontotemporal lobar degeneration. In the cerebellum, our analysis suggested that transcripts were less likely to be truncated and, excitingly, we discovered that intron containing transcripts were associated with poly(GP) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.33, p = 0.02, and (intron 1b): r = 0.49, p = 0.0004] and poly(GA) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.34, p = 0.02, and (intron 1b): r = 0.38, p = 0.007]. In summary, we report decreased expression of specific C9ORF72 transcripts and provide support for the presence of truncated transcripts as well as pre-mRNAs that may serve as templates for RAN translation. We further show that higher C9ORF72 levels may have beneficial effects, which warrants caution in the development of new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)863-876
Number of pages14
JournalActa Neuropathologica
Volume130
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Chromosomes, Human, Pair 9
Introns
Open Reading Frames
Cerebellum
Frontal Lobe
Exons
Real-Time Polymerase Chain Reaction
Frontotemporal Lobar Degeneration
RNA Precursors
Immunoassay
Genetic Promoter Regions

Keywords

  • Amyotrophic lateral sclerosis
  • C9ORF72
  • Disease modifier
  • Frontotemporal dementia
  • Frontotemporal lobar degeneration
  • Motor neuron disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. / Van Blitterswijk, Marka; Gendron, Tania D; Baker, Matthew C.; DeJesus-Hernandez, Mariely; Finch, NiCole C A; Brown, Patricia H.; Daughrity, Lillian M.; Murray, Melissa E; Heckman, Michael G.; Jiang, Jie; Lagier-Tourenne, Clotilde; Edbauer, Dieter; Cleveland, Don W.; Josephs, Keith Anthony; Parisi, Joseph E; Knopman, David S; Petersen, Ronald Carl; Petrucelli, Leonard; Boeve, Bradley F; Graff Radford, Neill R; Boylan, Kevin B.; Dickson, Dennis W; Rademakers, Rosa V.

In: Acta Neuropathologica, Vol. 130, No. 6, 01.12.2015, p. 863-876.

Research output: Contribution to journalArticle

Van Blitterswijk, Marka ; Gendron, Tania D ; Baker, Matthew C. ; DeJesus-Hernandez, Mariely ; Finch, NiCole C A ; Brown, Patricia H. ; Daughrity, Lillian M. ; Murray, Melissa E ; Heckman, Michael G. ; Jiang, Jie ; Lagier-Tourenne, Clotilde ; Edbauer, Dieter ; Cleveland, Don W. ; Josephs, Keith Anthony ; Parisi, Joseph E ; Knopman, David S ; Petersen, Ronald Carl ; Petrucelli, Leonard ; Boeve, Bradley F ; Graff Radford, Neill R ; Boylan, Kevin B. ; Dickson, Dennis W ; Rademakers, Rosa V. / Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. In: Acta Neuropathologica. 2015 ; Vol. 130, No. 6. pp. 863-876.
@article{157aee6368734d6a8338211ab4240ab0,
title = "Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72",
abstract = "The loss of chromosome 9 open reading frame 72 (C9ORF72) expression, associated with C9ORF72 repeat expansions, has not been examined systematically. Three C9ORF72 transcript variants have been described thus far; the GGGGCC repeat is located between two non-coding exons (exon 1a and exon 1b) in the promoter region of transcript variant 2 (NM_018325.4) or in the first intron of variant 1 (NM_145005.6) and variant 3 (NM_001256054.2). We studied C9ORF72 expression in expansion carriers (n = 56) for whom cerebellum and/or frontal cortex was available. Using quantitative real-time PCR and digital molecular barcoding techniques, we assessed total C9ORF72 transcripts, variant 1, variant 2, variant 3, and intron containing transcripts [upstream of the expansion (intron 1a) and downstream of the expansion (intron 1b)]; the latter were correlated with levels of poly(GP) and poly(GA) proteins aberrantly translated from the expansion as measured by immunoassay (n = 50). We detected a decrease in expansion carriers as compared to controls for total C9ORF72 transcripts, variant 1, and variant 2: the strongest association was observed for variant 2 (quantitative real-time PCR cerebellum: median 43 {\%}, p = 1.26e-06, and frontal cortex: median 58 {\%}, p = 1.11e-05; digital molecular barcoding cerebellum: median 31 {\%}, p = 5.23e-10, and frontal cortex: median 53 {\%}, p = 5.07e-10). Importantly, we revealed that variant 1 levels greater than the 25th percentile conferred a survival advantage [digital molecular barcoding cerebellum: hazard ratio (HR) 0.31, p = 0.003, and frontal cortex: HR 0.23, p = 0.0001]. When focusing on intron containing transcripts, analysis of the frontal cortex revealed an increase of potentially truncated transcripts in expansion carriers as compared to controls [digital molecular barcoding frontal cortex (intron 1a): median 272 {\%}, p = 0.003], with the highest levels in patients pathologically diagnosed with frontotemporal lobar degeneration. In the cerebellum, our analysis suggested that transcripts were less likely to be truncated and, excitingly, we discovered that intron containing transcripts were associated with poly(GP) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.33, p = 0.02, and (intron 1b): r = 0.49, p = 0.0004] and poly(GA) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.34, p = 0.02, and (intron 1b): r = 0.38, p = 0.007]. In summary, we report decreased expression of specific C9ORF72 transcripts and provide support for the presence of truncated transcripts as well as pre-mRNAs that may serve as templates for RAN translation. We further show that higher C9ORF72 levels may have beneficial effects, which warrants caution in the development of new therapeutic approaches.",
keywords = "Amyotrophic lateral sclerosis, C9ORF72, Disease modifier, Frontotemporal dementia, Frontotemporal lobar degeneration, Motor neuron disease",
author = "{Van Blitterswijk}, Marka and Gendron, {Tania D} and Baker, {Matthew C.} and Mariely DeJesus-Hernandez and Finch, {NiCole C A} and Brown, {Patricia H.} and Daughrity, {Lillian M.} and Murray, {Melissa E} and Heckman, {Michael G.} and Jie Jiang and Clotilde Lagier-Tourenne and Dieter Edbauer and Cleveland, {Don W.} and Josephs, {Keith Anthony} and Parisi, {Joseph E} and Knopman, {David S} and Petersen, {Ronald Carl} and Leonard Petrucelli and Boeve, {Bradley F} and {Graff Radford}, {Neill R} and Boylan, {Kevin B.} and Dickson, {Dennis W} and Rademakers, {Rosa V}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s00401-015-1480-6",
language = "English (US)",
volume = "130",
pages = "863--876",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72

AU - Van Blitterswijk, Marka

AU - Gendron, Tania D

AU - Baker, Matthew C.

AU - DeJesus-Hernandez, Mariely

AU - Finch, NiCole C A

AU - Brown, Patricia H.

AU - Daughrity, Lillian M.

AU - Murray, Melissa E

AU - Heckman, Michael G.

AU - Jiang, Jie

AU - Lagier-Tourenne, Clotilde

AU - Edbauer, Dieter

AU - Cleveland, Don W.

AU - Josephs, Keith Anthony

AU - Parisi, Joseph E

AU - Knopman, David S

AU - Petersen, Ronald Carl

AU - Petrucelli, Leonard

AU - Boeve, Bradley F

AU - Graff Radford, Neill R

AU - Boylan, Kevin B.

AU - Dickson, Dennis W

AU - Rademakers, Rosa V

PY - 2015/12/1

Y1 - 2015/12/1

N2 - The loss of chromosome 9 open reading frame 72 (C9ORF72) expression, associated with C9ORF72 repeat expansions, has not been examined systematically. Three C9ORF72 transcript variants have been described thus far; the GGGGCC repeat is located between two non-coding exons (exon 1a and exon 1b) in the promoter region of transcript variant 2 (NM_018325.4) or in the first intron of variant 1 (NM_145005.6) and variant 3 (NM_001256054.2). We studied C9ORF72 expression in expansion carriers (n = 56) for whom cerebellum and/or frontal cortex was available. Using quantitative real-time PCR and digital molecular barcoding techniques, we assessed total C9ORF72 transcripts, variant 1, variant 2, variant 3, and intron containing transcripts [upstream of the expansion (intron 1a) and downstream of the expansion (intron 1b)]; the latter were correlated with levels of poly(GP) and poly(GA) proteins aberrantly translated from the expansion as measured by immunoassay (n = 50). We detected a decrease in expansion carriers as compared to controls for total C9ORF72 transcripts, variant 1, and variant 2: the strongest association was observed for variant 2 (quantitative real-time PCR cerebellum: median 43 %, p = 1.26e-06, and frontal cortex: median 58 %, p = 1.11e-05; digital molecular barcoding cerebellum: median 31 %, p = 5.23e-10, and frontal cortex: median 53 %, p = 5.07e-10). Importantly, we revealed that variant 1 levels greater than the 25th percentile conferred a survival advantage [digital molecular barcoding cerebellum: hazard ratio (HR) 0.31, p = 0.003, and frontal cortex: HR 0.23, p = 0.0001]. When focusing on intron containing transcripts, analysis of the frontal cortex revealed an increase of potentially truncated transcripts in expansion carriers as compared to controls [digital molecular barcoding frontal cortex (intron 1a): median 272 %, p = 0.003], with the highest levels in patients pathologically diagnosed with frontotemporal lobar degeneration. In the cerebellum, our analysis suggested that transcripts were less likely to be truncated and, excitingly, we discovered that intron containing transcripts were associated with poly(GP) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.33, p = 0.02, and (intron 1b): r = 0.49, p = 0.0004] and poly(GA) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.34, p = 0.02, and (intron 1b): r = 0.38, p = 0.007]. In summary, we report decreased expression of specific C9ORF72 transcripts and provide support for the presence of truncated transcripts as well as pre-mRNAs that may serve as templates for RAN translation. We further show that higher C9ORF72 levels may have beneficial effects, which warrants caution in the development of new therapeutic approaches.

AB - The loss of chromosome 9 open reading frame 72 (C9ORF72) expression, associated with C9ORF72 repeat expansions, has not been examined systematically. Three C9ORF72 transcript variants have been described thus far; the GGGGCC repeat is located between two non-coding exons (exon 1a and exon 1b) in the promoter region of transcript variant 2 (NM_018325.4) or in the first intron of variant 1 (NM_145005.6) and variant 3 (NM_001256054.2). We studied C9ORF72 expression in expansion carriers (n = 56) for whom cerebellum and/or frontal cortex was available. Using quantitative real-time PCR and digital molecular barcoding techniques, we assessed total C9ORF72 transcripts, variant 1, variant 2, variant 3, and intron containing transcripts [upstream of the expansion (intron 1a) and downstream of the expansion (intron 1b)]; the latter were correlated with levels of poly(GP) and poly(GA) proteins aberrantly translated from the expansion as measured by immunoassay (n = 50). We detected a decrease in expansion carriers as compared to controls for total C9ORF72 transcripts, variant 1, and variant 2: the strongest association was observed for variant 2 (quantitative real-time PCR cerebellum: median 43 %, p = 1.26e-06, and frontal cortex: median 58 %, p = 1.11e-05; digital molecular barcoding cerebellum: median 31 %, p = 5.23e-10, and frontal cortex: median 53 %, p = 5.07e-10). Importantly, we revealed that variant 1 levels greater than the 25th percentile conferred a survival advantage [digital molecular barcoding cerebellum: hazard ratio (HR) 0.31, p = 0.003, and frontal cortex: HR 0.23, p = 0.0001]. When focusing on intron containing transcripts, analysis of the frontal cortex revealed an increase of potentially truncated transcripts in expansion carriers as compared to controls [digital molecular barcoding frontal cortex (intron 1a): median 272 %, p = 0.003], with the highest levels in patients pathologically diagnosed with frontotemporal lobar degeneration. In the cerebellum, our analysis suggested that transcripts were less likely to be truncated and, excitingly, we discovered that intron containing transcripts were associated with poly(GP) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.33, p = 0.02, and (intron 1b): r = 0.49, p = 0.0004] and poly(GA) levels [digital molecular barcoding cerebellum (intron 1a): r = 0.34, p = 0.02, and (intron 1b): r = 0.38, p = 0.007]. In summary, we report decreased expression of specific C9ORF72 transcripts and provide support for the presence of truncated transcripts as well as pre-mRNAs that may serve as templates for RAN translation. We further show that higher C9ORF72 levels may have beneficial effects, which warrants caution in the development of new therapeutic approaches.

KW - Amyotrophic lateral sclerosis

KW - C9ORF72

KW - Disease modifier

KW - Frontotemporal dementia

KW - Frontotemporal lobar degeneration

KW - Motor neuron disease

UR - http://www.scopus.com/inward/record.url?scp=84947614093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947614093&partnerID=8YFLogxK

U2 - 10.1007/s00401-015-1480-6

DO - 10.1007/s00401-015-1480-6

M3 - Article

C2 - 26437865

AN - SCOPUS:84947614093

VL - 130

SP - 863

EP - 876

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 6

ER -